Table 3 Association between irinotecan sensitivity and clinical characteristics
Characteristic | Irinotecan inhibition rate | Irinotecan inhibition rate |
|---|---|---|
| Â | mean (95% CI) | mean (95% CI) |
|  | Training set (N = 100) | Independent testing set (N = 75) |
Age, y median (range) | Â | Â |
 ≥ 63 | 42% (36–47%) | 44% (31–57%) |
 < 63 | 45% (39–51%) | 44% (34–54%) |
Sex | Â | Â |
 Male | 43% (38–47%) | 42% (33–51%) |
 Female | 45% (36–55%) | 50% (31–68%) |
Tumor Site | Â | Â |
 Distal stomach | 42% (35–49%) | 44% (28–60%) |
 Proximal stomach | 44% (38–51%) | 47% (35–58%) |
 Whole stomach | 43% (35–51%) | 37% (16–59%) |
Stage | Â | Â |
 I | 34% (21–47%) | 36% (3–70%) |
 II | 49% (40–57%) | 50% (31–68%) |
 III | 43% (38–48%) | 44% (34–54%) |
 IV | 33% | 34% |
Histological grade | Â | Â |
 2 | 41% (33–49%) | 44% (21–68%) |
 3 | 42% (36–48%) | 39% (27–51%) |
 Mixed 1–2 | 54% | 58% |
 Mixed 2–3 | 46% (38–54%) | 49% (35–62%) |
Lymph node metastasis | Â | Â |
 No | 42% (33–51%) | 46% (27–65%) |
 Yes | 44% (39–48%) | 44% (34–53%) |
Signature index | Â | Â |
 > 0.43 | 57% (52–63%) ** | 65% (61–70%) ** |
 ≤ 0.43 | 31% (27–36%) | 22% (17–28%) |